Best GLP-1 for Type 2 Diabetes in 2026: Comparing What the Data Shows

GLP-1 receptor agonists are now first-line pharmacotherapy for type 2 diabetes in many clinical algorithms, ahead of or alongside metformin, for patients who need A1C reduction and can benefit from weight loss, cardiovascular risk reduction, or both. The choice between them depends on the clinical priority and what the insurance will support.

This page maps the FDA-approved T2D GLP-1 options, what the head-to-head data shows, and how to think about the clinical trade-offs.

The approved T2D GLP-1 drugs

Four GLP-1 receptor agonists are currently FDA-approved for type 2 diabetes:

Exenatide (Byetta/Bydureon) is also approved but rarely used as a first-choice option given the newer agents.

Tirzepatide (Mounjaro): the strongest efficacy data

Tirzepatide is the dual GLP-1 + GIP receptor agonist. The GIP activation adds a metabolic dimension that GLP-1 alone does not provide: improving insulin sensitivity in adipose tissue independently of weight loss, promoting energy expenditure via brown adipose tissue, and producing robust reductions in fasting triglycerides. The full mechanism is covered in How Tirzepatide Works.

A1C reduction in T2D

SURPASS-2 — the direct head-to-head against semaglutide 1 mg in 1,879 participants — showed:

• Tirzepatide 5 mg: −2.0% vs semaglutide 1 mg: −1.9%
• Tirzepatide 10 mg: −2.2%
• Tirzepatide 15 mg: −2.3%

Across the SURPASS programme, up to 92% of tirzepatide patients achieved A1C below 7% at the highest doses. Up to 51% achieved A1C below 5.7% — effectively non-diabetic glycaemic range.

Weight loss in T2D

SURPASS-2: tirzepatide 15 mg produced −11.2 kg vs −5.7 kg for semaglutide 1 mg. In the real-world 72-week JAMA Internal Medicine study, tirzepatide produced 20.2% body weight loss vs 13.7% for semaglutide.

The gap Tirzepatide cannot yet fill

Tirzepatide does not have an FDA-approved cardiovascular risk-reduction indication for T2D. The SURPASS-CVOT trial is ongoing. Until those results are reviewed, prescribers managing T2D patients with established CVD who want a label-supported cardiovascular benefit need to consider semaglutide.

Semaglutide injectable (Ozempic): the CV indication and established record

Ozempic (semaglutide) has been FDA-approved for T2D since December 2017 — the longest real-world safety record of any GLP-1 currently on this list. It added a cardiovascular risk-reduction indication in January 2020 based on SUSTAIN-6: 26% relative risk reduction in MACE (major adverse cardiovascular events) in T2D patients with established cardiovascular disease.

For T2D patients with known heart disease — post-MI, history of stroke, peripheral arterial disease — Ozempic's approved CV indication is a real clinical differentiator from tirzepatide today.

A1C reduction

−1.3% to −2.0% across SUSTAIN trials, depending on dose and comparator. At the 2 mg dose (maximum for Ozempic), A1C reduction is approximately 1.9% — similar to tirzepatide 5 mg, below tirzepatide 10–15 mg.

Weight loss in T2D

−3.6 to −6.1 kg in SUSTAIN trials. Lower than tirzepatide at comparable doses, reflecting both the lower dose ceiling (2 mg vs 15 mg) and the absence of GIP agonism.

Insulin sensitivity note

Ozempic's single-mechanism (GLP-1 only) approach does not provide the direct adipose-insulin-sensitivity improvement that GIP agonism adds. For T2D patients with significant insulin resistance beyond beta-cell dysfunction, this is a mechanistic limitation.

Semaglutide oral (Rybelsus): for injection-averse patients

Rybelsus (oral semaglutide) is FDA-approved for T2D at 3, 7, and 14 mg once-daily tablets. At 14 mg, A1C reduction is approximately −1.4%. Weight loss is approximately −4 to −5 kg at 14 mg in T2D trials.

Efficacy is lower than injectable semaglutide at equivalent doses because oral bioavailability is approximately 1% — the stomach acid degrades most of the peptide. The 14 mg oral dose roughly corresponds to the 0.5–1 mg injectable dose pharmacodynamically.

Dosing constraint: Rybelsus must be taken on waking with no more than 4 oz of plain water. Food, coffee, other medications, or additional water within 30 minutes substantially reduce absorption. This is a real adherence constraint in daily life.

Rybelsus is not the same as oral Wegovy (semaglutide 50 mg for obesity). The two products have different doses, different indications, and different bioavailability workarounds.

For T2D patients with needle phobia or preference for oral medication, Rybelsus provides GLP-1 T2D efficacy without injection. The trade-off is lower efficacy and a strict dosing protocol.

Dulaglutide (Trulicity): the cardiac-event data with a simpler device

Dulaglutide (Trulicity) is FDA-approved for T2D and has its own cardiovascular outcomes data — REWIND trial (2019) showed 12% relative risk reduction in MACE vs placebo in T2D patients. This is a lower relative risk reduction than semaglutide's 26% in SUSTAIN-6, but it applies to a broader population including patients without established CVD.

Trulicity's device (pre-filled, auto-injector pen) is often cited as easier to use than earlier GLP-1 devices. The 0.75 mg to 4.5 mg dose range provides flexibility.

A1C reduction at 4.5 mg: approximately −1.2 to −1.5%. Weight loss: −3 to −5 kg. Both are below tirzepatide and comparable to lower-dose semaglutide.

For T2D patients with primarily cardiovascular risk goals who also want weight loss and prefer a simple injection device, Trulicity is a reasonable option. For maximum A1C and weight-loss efficacy, tirzepatide is ahead.

How the insurance picture works for T2D

Commercial insurance typically covers all the drugs above for T2D with prior authorisation or step therapy requirements. Manufacturer savings cards bring out-of-pocket costs to $25/month or less:

• Mounjaro Savings Card (tirzepatide, T2D label): ~$25/month, commercial insurance only
• Ozempic SteadyStart (semaglutide, T2D label): similar commercial copay assistance
• Rybelsus Savings Card: similar

Medicare Part D covers T2D-indicated GLP-1s. Note: Medicare coverage for obesity-labelled products (Zepbound, Wegovy) is different and more limited — see the Medicare GLP-1 coverage guide.

Choosing between them: clinical framework

The prescriber's decision depends on:

This is not a clinical recommendation — prescribing decisions involve your full medical history, comorbidities, kidney function, other medications, and clinical picture. The framework above summarises how the published data maps to clinical priorities; discuss with your prescriber how that maps to your situation.

For a deeper comparison of the GLP-1 + GIP mechanism versus GLP-1 alone, see Ozempic vs Mounjaro. For T2D patients also seeking weight-loss label coverage, see Mounjaro vs Zepbound.